Use of Healthy Volunteers in Oncology Drug Development: A Case Study

Weiwei Tan, Ph.D.
Introduction

- Phase 1 first-in-human dose-escalating studies with investigational oncology drugs are typically conducted in patients with advanced cancer.

- Development of molecularly targeted, non-cytotoxic anticancer therapeutics offers scope for clinical investigation in healthy volunteers.

- Trials in these populations can provide useful safety, PK, DDI, Food Effect and possibly PD data to help guide further clinical development.
PF-04217903: c-Met/HGFR Inhibitor

- Ligand Binding

- PF-03 is a small molecule, selective, ATP-competitive inhibitor of the c-Met/HGFR.

- PF-03 was not genotoxic based on a standard battery of assays for mutagenicity and clastogenicity.

Clinical Studies

- **Study 1001**
  - A Phase 1, Double-Blind, Escalating Single Dose, Safety, Tolerability, and Pharmacokinetic Study of PF-03 in Healthy Adult Volunteers
    
    *(Tan W et al, ASCPT Poster 2009)*

- **Study 1002 [NCT00706355]**
  - A Phase 1, Escalating Multiple Dose, Safety, Tolerability, and Pharmacokinetic Study of PF-03 in Patients with Advanced Solid Tumors
    
    *(Diamond JR et al, JCO v31, 2013)*
Study 1001 in Healthy Volunteers

• To evaluate the safety and tolerability of escalating single doses of PF-03 when administered to healthy adult subjects.

• To evaluate the PK of PF-03 and its metabolite (if present) after escalating single doses of PF-03, administered to healthy adult subjects under fed and fasted conditions.
Study Design

- Randomized, placebo-controlled, double-blind, single-dose escalation study with a parallel-group design.
- Subjects within each cohort were randomly assigned to receive one dose of either PF-03 (n=6) or placebo (n=2).
- Dosing in subsequent cohorts began at least 7 days after dosing in the prior cohort, in the absence of dose-limiting AEs in two or more subjects.
- All subjects were fasted except that the 6 subjects in the food effect cohort
- Blood and urine samples were collected and analyzed for concentrations of PF-03 and its metabolite.
Starting Dose and Stopping Dose

- **Starting dose: 1 mg**
  - EC\textsubscript{10} = 2.2 nM (free concentration) or 4.9 ng/mL (total concentration)
  - EC\textsubscript{10} dose = 0.7 mg (rounded to 1 mg) using predicted human PK parameters
  - Expected to produce no or minimal pharmacologic effect

- **Stopping dose: 700 mg**
  - NOAEL exposure in the 7-day dog toxicity study: 3.3 µg/mL (C\textsubscript{max}) and 13 µg·h/mL (AUC)
  - Stopping dose was determined to be 717 mg (rounded to 700 mg)
# Dose Escalations

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Number of Subjects</th>
<th>Treatment</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F (Food Effect)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6</td>
<td>1 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>4 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>8 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>240 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Placebo</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X mg *</td>
</tr>
</tbody>
</table>
A total of **70** subjects: 16 received placebo and 54 received escalating doses of PF-03 ranging from 1 mg to 240 mg

**Inclusion Criteria:**
- Healthy men or women of non-childbearing potential
- Age: 18–55 years.
- Body mass index: 18–30 kg/m²; body weight: ≥50 kg
- Normal creatinine clearance during screening
- Plasma troponin I concentration <0.04 ng/mL, due to microscopic changes in the heart from a preclinical toxicology study in dogs

**Exclusion Criteria:**
- History of clinically significant disease (hepatitis B or C)
- Male subjects with conditions that might affect fertility
- QTc >450 ms
- Regular consumption of alcohol or tobacco products
- Investigational drug within 30 days
- Prescription or non-prescription drugs within 7 days
Pharmacokinetic Results

- PF-03 absorption was rapid, median $T_{\text{max}}$ of 1-2 hrs.
- PF-03 $C_{\text{max}}$ and $AUC_{\text{inf}}$ appeared to increase proportionally with dose ranging from 4 mg to 120 mg.
- $T_{1/2} \sim 8$ hrs
- Formation of metabolite PF-029 was rapid, median $T_{\text{max}}$ of 1-2.5 hrs.
- M/P ratio ranged from 0.16 to 0.24.
- High-fat meal increased $C_{\text{max}}$ and delayed median $T_{\text{max}}$ by ~3 hrs, but did not change $AUC_{\text{inf}}$.
- The urinary excretion of PF-03 was negligible (1%).
Safety Results

• There were no deaths, SAEs, or withdrawals due to AEs reported in this study and no subject had a severe AE.

• No laboratory abnormalities seemed to be dose-dependent and some abnormalities were noted in placebo-treated subjects.

• No consistent trends by dose or by time point were noted for mean changes from baseline in vital signs, BP, and ECG results.

• PF-03 doses up to 120 mg were safe and well tolerated.

• Clinically significant elevations in ALT/AST were reported for 2 subjects in the 240 mg fasted group. These dose-limiting AEs, in conjunction with PK data from the 120 and 240 mg doses, led to a decision that dose escalation would not be continued beyond 240 mg.
Study 1002 in Advanced Cancer Patients

• Determine the safety profile of PF-03
  – Identify MTD
  – Identify RP2D

• Determine the multiple-dose PK profile of PF-03

• Determine any evidence of anti-tumor activity of PF-03

• Perform exploratory evaluations of c-Met/HGFR genotyping and expression, PD endpoints and biomarkers of PF-03
Starting Dose Selection in Patients

- **Starting dose = 280 mg daily (DeGeorge algorithm)**
  - One-sixth of the highest dose evaluated in dogs that did not cause severe, irreversible toxicity.

- **Starting dose = 50 mg BID (Using data from Study 1001)**
  - Exceeding the predicted efficacious drug concentration of 83 ng/mL for at least 50% of the dosing interval.
  - Below the lowest observed AUC from 0 to 24 hours and $C_{\text{max}}$ at which dose-limiting AEs were observed in HVs.

- In Study 1002, MTD = 100 mg BID and MAD = 150 mg BID
# Data from Healthy Volunteer Study to Support Cancer Patient Study

<table>
<thead>
<tr>
<th>FIH Study</th>
<th>FIP Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>PK</td>
<td>Starting Dose/Regimen</td>
</tr>
<tr>
<td>Food Effect/Formulation</td>
<td>Dose Administration</td>
</tr>
<tr>
<td>Safety (limited)</td>
<td>MTD</td>
</tr>
<tr>
<td>Biomarkers</td>
<td>Early Efficacy</td>
</tr>
</tbody>
</table>
First-in-Human to First-in-Patient

- FIH Data
- Starting Dose
- Clinical Dose
- MTD
- FIP Dose Escalation
Thank You!